This narrative review explores the metabolic effects of GLP-1 RAs in weight management, blood glucose, cardiovascular health, lipid profiles, and blood pressure.
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2 diabetes mellitus, show promise in promoting weight loss and improving heart health in obese individuals without diabetes.
Furthermore, it discusses the impact of GLP-1 receptor agonists on obesity-related comorbidities, their comparison with other pharmacological treatments, and future perspectives.
Effects of GLP-1s on these disorders are not well established, and could theoretically reduce or exacerbate symptoms in different circumstances.Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med.
Currently, research on anti-obesity effect of modified GLP-1 RAs has grown significantly, liraglutide accounts for approximately 56% of the global obesity drug market. Long-acting analogues and multifunctional peptides showed good weight loss activity.
GLP-1 agonists are synthetic medications that mimic the effects of natural GLP-1. Unlike GLP-1, which has a short half-life, these agonists have a longer duration of action.
Glucogen-like peptide 1 (GLP-1) agonists have proved effective in helping obese people lose weight by reducing the users' appetite, so they eat less. But alongside the hype, there have also been claims that we can easily mimic the drugs' effects with the foods we eat.
